Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab in pediatric severe plaque psoriasis
NCT03240809Phase 4Active, not recruiting
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of brodalumab in plaque psoriasis, sponsored by Valeant Pharmaceuticals. Started Jan 2020; status: active, not recruiting.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03240809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240809.